Boston, MA headquartered AI vocal biomarker company Sonde Health raised a $19.25 million Series B investment round led by Seoul-based venture capital firm, Partners Investment.
Others that invested were NEOM Company, KT Corporation, and existing investors, including co-founder PureTech Health and M Ventures. The company raised $35.25 million in total.
The company will use the funding to drive its global commercial growth, deepen its respiratory and mental health monitoring technologies, and build capabilities for additional health conditions. It will globalize its voice-based disease screening technology with partners in Korea and India.
Mumbai, India-based Koye Pharmaceuticals, which had already engaged Sonde to develop a COPD vocal biomarker, has expanded the partnership to develop a novel mental health vocal biomarker for deployment in India.
David Liu CEO of Sonde Health said, “Digital biomarkers are becoming a mainstay in healthcare. Today’s healthcare companies are realizing how vocal biomarkers can engage people earlier in their health. The data and insights found in voice can power health monitoring and patient stratification so issues can become apparent well before a costly medical event occurs. “With voice and any listening device, accessible and effective health monitoring can be made available to the majority of the world.”
Sonde is the only biomarker company to offer AI/machine learning-based monitoring products for multiple health conditions and to have developed the ability to embed its technology into device chipsets for passive and safe health monitoring through voice.
Sonde provides its enterprise vocal biomarker technology to companies across several health verticals, including telehealth, pharmaceutical, remote patient monitoring, and consumer/medical devices.
Last updated: December 26th, 2025
